Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Alpine Immune Sciences management to meet virtually with Wedbush » 04:55
07/01/20
07/01
04:55
07/01/20
04:55
ALPN

Alpine Immune Sciences

$9.62 /

+0.71 (+7.97%)

Virtual Meeting to be…

Virtual Meeting to be held on July 1 hosted by Wedbush.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$9.62 /

+0.71 (+7.97%)

ALPN Alpine Immune Sciences
$9.62 /

+0.71 (+7.97%)

06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
ALPN Alpine Immune Sciences
$9.62 /

+0.71 (+7.97%)

ALPN Alpine Immune Sciences
$9.62 /

+0.71 (+7.97%)

Friday
Conference/Events
Alpine Immune Sciences management to meet virtually with Wedbush » 08:57
06/26/20
06/26
08:57
06/26/20
08:57
ALPN

Alpine Immune Sciences

$9.21 /

-0.895 (-8.86%)

Virtual Meeting to be…

Virtual Meeting to be held on July 1 hosted by Wedbush.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$9.21 /

-0.895 (-8.86%)

ALPN Alpine Immune Sciences
$9.21 /

-0.895 (-8.86%)

06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
ALPN Alpine Immune Sciences
$9.21 /

-0.895 (-8.86%)

ALPN Alpine Immune Sciences
$9.21 /

-0.895 (-8.86%)

Over a week ago
Hot Stocks
Alpine Immune Sciences announces first patient dosed in NEON-1 study » 08:06
06/24/20
06/24
08:06
06/24/20
08:06
ALPN

Alpine Immune Sciences

$10.59 /

-1.205 (-10.22%)

Alpine Immune Sciences…

Alpine Immune Sciences announced that the first patient has been dosed in its NEON-1 Phase 1 study of ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in patients with advanced malignancies.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$10.59 /

-1.205 (-10.22%)

ALPN Alpine Immune Sciences
$10.59 /

-1.205 (-10.22%)

06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
ALPN Alpine Immune Sciences
$10.59 /

-1.205 (-10.22%)

ALPN Alpine Immune Sciences
$10.59 /

-1.205 (-10.22%)

Recommendations
Alpine Immune price target raised to $22 from $10 at Wedbush » 07:50
06/19/20
06/19
07:50
06/19/20
07:50
ALPN

Alpine Immune Sciences

$10.75 /

+6.05 (+128.72%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll raised the firm's price target on Alpine Immune (ALPN) to $22 from $10 and keeps an Outperform rating on the shares following the announcement of a licensing agreement with AbbVie (ABBV) for ALPN-101. The analyst sees the agreement as a vote of confidence in ALPN-101, but also as providing significant validation of the company's flexible Directed Evolution discovery platform.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$10.75 /

+6.05 (+128.72%)

ALPN Alpine Immune Sciences
$10.75 /

+6.05 (+128.72%)

06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ALPN Alpine Immune Sciences
$10.75 /

+6.05 (+128.72%)

ALPN Alpine Immune Sciences
$10.75 /

+6.05 (+128.72%)

Recommendations
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler » 11:42
06/18/20
06/18
11:42
06/18/20
11:42
ALPN

Alpine Immune Sciences

$8.85 /

+4.15 (+88.30%)

, ABBV

AbbVie

$95.90 /

+0.14 (+0.15%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Alpine Immune Sciences (ALPN) to $21 from $8 and reiterates an Overweight rating on the shares after the company announced an option agreement with AbbVie (ABBV) for ALPN-101. The stock in midday trading is up 101% to $9.79. The deal broadly validates Alpine's novel variant Immunoglobulin domain platform, Tenthoff tells investors in a research note. The analyst points out that Alpine will receive $60M upfront and is eligible for up to $805M in milestones. He estimates the company now holds pro forma cash of $96M to fund operations into 2023.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$8.85 /

+4.15 (+88.30%)

ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

ALPN Alpine Immune Sciences
$8.85 /

+4.15 (+88.30%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
ALPN Alpine Immune Sciences
$8.85 /

+4.15 (+88.30%)

ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

ALPN Alpine Immune Sciences
$8.85 /

+4.15 (+88.30%)

ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

ABBV AbbVie
$95.90 /

+0.14 (+0.15%)

Conference/Events
Alpine Immune Sciences to host conference call » 08:36
06/18/20
06/18
08:36
06/18/20
08:36
ALPN

Alpine Immune Sciences

$4.70 /

+0.62 (+15.20%)

, ABBV

AbbVie

$95.76 /

-0.4 (-0.42%)

Conference call to…

Conference call to discuss the option and license agreement with AbbVie for the development and commercialization of ALPN-101 will be held on June 18 at 8:30 am. Webcast Link

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

Hot Stocks
Alpine Immune Sciences Inc trading resumes  08:30
06/18/20
06/18
08:30
06/18/20
08:30
ALPN

Alpine Immune Sciences

$4.70 /

+0.62 (+15.20%)

 
ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

Hot Stocks
Alpine Immune Sciences, AbbVie announce exclusive license agreement for ALPN-101 » 08:15
06/18/20
06/18
08:15
06/18/20
08:15
ALPN

Alpine Immune Sciences

$4.70 /

+0.62 (+15.20%)

, ABBV

AbbVie

$95.76 /

-0.4 (-0.42%)

Alpine Immune Sciences…

Alpine Immune Sciences (ALPN) and AbbVie (ABBV) announced an exclusive worldwide option and license agreement for ALPN-101, a dual CD28/ICOS costimulation antagonist. CD28 and ICOS are costimulatory molecules that likely play roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. Favorable safety and tolerability, pharmacokinetics and pharmacodynamics have been observed in a first-in-human study in adult healthy volunteers. Under the terms of the agreement, Alpine will receive an upfront payment of $60M, and will also be eligible to receive up to an aggregate of $805M for exercise of the option and success-based development, regulatory and commercial milestones. In addition, Alpine is eligible to receive tiered royalties on net sales of ALPN-101. In exchange, AbbVie will receive an option to an exclusive license for ALPN-101. During the option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

Hot Stocks
Alpine Immune Sciences Inc trading halted, news pending  07:57
06/18/20
06/18
07:57
06/18/20
07:57
ALPN

Alpine Immune Sciences

$4.70 /

+0.62 (+15.20%)

 
ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

ALPN Alpine Immune Sciences
$4.70 /

+0.62 (+15.20%)

Hot Stocks
Alpine Immune Sciences presents updated ALPN-101 results at EULAR » 08:19
06/08/20
06/08
08:19
06/08/20
08:19
ALPN

Alpine Immune Sciences

$3.98 /

+0.09 (+2.31%)

Alpine Immune Sciences…

Alpine Immune Sciences presented updated results from its Phase 1 healthy volunteer study of ALPN-101, the company's first-in-class dual CD28/ICOS costimulation antagonist for the treatment of autoimmune and inflammatory diseases. The poster was presented during the SLE, Sjogren's and APS treatment poster session of the European League Against Rheumatism, or EULAR, E-Congress. This first-in-human study randomized 96 healthy adults to receive single or multiple, intravenous or subcutaneous, placebo or ALPN-101 at doses ranging from 1 microgram/kg to 10 mg/kg. At all dose levels, ALPN-101 was well tolerated with no severe adverse events, clinically-significant immunogenicity events, or evidence of cytokine release. Pharmacokinetics and pharmacodynamics exhibited desirable dose dependence, with increasing doses corresponding to increasing duration of complete or near-complete target saturation, as well as inhibition of antibody responses to keyhole limpet hemocyanin immunization.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$3.98 /

+0.09 (+2.31%)

ALPN Alpine Immune Sciences
$3.98 /

+0.09 (+2.31%)

06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
ALPN Alpine Immune Sciences
$3.98 /

+0.09 (+2.31%)

ALPN Alpine Immune Sciences
$3.98 /

+0.09 (+2.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.